The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention.
Abstract
OBJECTIVE
To evaluate the benefit of mass eradication of Helicobacter pylori infection in reducing premalignant gastric lesions.
DESIGN
Mass eradication of H pylori infection was started from 2004 for a Taiwanese population with prevalent H pylori infection,
who were >30 years of age. Participants positive for the (13)C-urea breath test underwent endoscopic screening and 1-week
clarithromycin-based triple therapy. For subjects whose initial treatment failed, 10-day levofloxacin-based triple therapy
was administered. The main outcome measures were changes in the prevalence of H pylori infection and premalignant gastric
lesions, and changes in the incidence of premalignant gastric lesions and gastric cancer before (1995-2003) and after (2004-2008)
chemoprevention using various comparators.
RESULTS
The reduction in H pylori infection was 78.7% (95% CI 76.8% to 80.7%), and the estimated incidence of re-infection/recrudescence
was 1% (95% CI 0.6% to 1.4%) per person-year. The effectiveness of reducing the incidence of gastric atrophy resulting from
chemoprevention was significant at 77.2% (95% CI 72.3% to 81.2%), while the reduction in intestinal metaplasia was not significant.
Compared with the 5-year period before chemoprevention and in the absence of endoscopic screening, the effectiveness in reducing
gastric cancer incidence during the chemoprevention period was 25% (rate ratio 0.753, 95% CI 0.372 to 1.524). The reduction
in peptic ulcer disease was 67.4% (95% CI 52.2% to 77.8%), while the incidence of oesophagitis was 6% (95% CI 5.1% to 6.9%)
after treatment.
CONCLUSIONS
Population-based eradication of H pylori infection has led to a significant reduction in gastric atrophy at the expense of
increased oesophagitis. The ultimate benefit in reducing gastric cancer incidence and its mortality should be validated by
a further long-term follow-up.
Links
Authors
Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, Wu MS, Lin JT
Institution
Division of Biostatistics, Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Source
Gut 62:5 2013 May pg 676-82Pub Type(s)
Journal ArticleResearch Support, Non-U.S. Gov't
Language
eng
PubMed ID
22698649
Log In

